Printer Friendly
The Free Library
22,728,960 articles and books

Research Corporation Technologies Announces Growing Use of Versatile Protein Expression Tool.

Business Editors & Health/Medical Writers


TUCSON, Ariz.--(BUSINESS WIRE)--Dec. 2, 2002

Research Corporation Technologies granted 38 new licenses in 2002 for use of a DNA DNA: see nucleic acid.
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 tool to increase protein expression levels in eukaryotic cells. To date, 78 biotechnology and pharmaceutical companies in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , Canada, Japan, Europe and Australia are licensed users of the bovine growth hormone bovine growth hormone
A naturally occurring hormone of cattle that regulates growth and milk production. It may also be produced artificially by genetic engineering techniques and administered to cows to increase milk production.
 polyadenylation signal sequence (bgh-polyA).

Researchers at Case Western Reserve University in Cleveland discovered the bgh-polyA, a specialized termination sequence that enables a high level of protein expression in mammalian cells. Derived from the bgh gene, the bgh-polyA sequence is a useful tool for producing pharmaceutical proteins and peptides in culture, increasing gene expression in gene therapy, and producing proteins in transgenic animals Transgenic animal
Animals that have had genes from other species inserted into their genetic code.

Mentioned in: Glycogen Storage Diseases
. Researchers have proven the effectiveness of the technology in a variety of systems.

RCT RCT Randomized Controlled Trial
RCT Regimental Combat Team (infantry regiment with their own artillery, engineers, medical and tanks)
RCT Rollercoaster Tycoon
RCT Randomized Clinical Trial
RCT Rhondda Cynon Taff
 manages commercialization of this technology for Case Western Reserve University and the inventors. In 1997, the university assigned RCT the rights to patents issued in the United States, Europe and Japan that broadly cover the composition of the polyadenylation sequence and its use.

All gene expression requires a promoter, a gene that encodes a protein and a termination sequence. While other auxiliary components are involved, the promoter, gene and termination sequences are the necessary minimum for gene expression. In mammalian cells, messenger RNA mes·sen·ger RNA
See mRNA.
 (mRNA) must be transported from the nucleus, where transcription occurs, to the cytoplasm cytoplasm: see protoplasm.

Portion of a eukaryotic cell outside the nucleus. The cytoplasm contains all the organelles (see eukaryote).
 for translation into protein. The bgh-polyA sequence signals the addition of a "tail" of adenine-containing nucleotides to the 3' end of the mRNA that stabilizes the mRNA for export to the cytoplasm. Upon reaching the cytoplasm, the polyA tail promotes protein translation and stabilizes the mRNA during protein expression.

The bgh-polyA sequence is part of RCT's Gene Expression Technologies (GET) licensing program, which offers systems and components for gene expression at affordable costs. The GET program offers flexible, nonexclusive licenses with manageable fees and fractional royalties based on fields of use.

For information about licensing the bgh-polyA sequence, contact Jennifer T. Caldwell, Ph.D., GET program senior analyst, 520/748-4441, 520/748-0025 fax,

Research Corporation Technologies in Tucson, is an independent technology management company that commercializes early-stage biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
 and photonics technologies worldwide. Commercialization vehicles include seed investments and venture development, partnerships, and specialized licensing programs.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 2, 2002
Previous Article:Business Objects Names New Vice President of European Operations.
Next Article:Acculent, Advanced Architectures, Paradigm, S3, and YogiTech Join Open Core Protocol International Partnership.

Related Articles
Tegal sells 900 Series etch system for biochip fab to Zyomyx.
Scimagix improves Scientific Image analysis.
Systems toxicology and the chemical effects in biological systems (CEBS) knowledge base.
RCT Hits Licensing Milestone for Essential Protein Expression Tool.
Minimize variations in product quality.
Mass spectrometry group has mass appeal.
The path to species comparison.
Open Biosystems' shRNAmir Technology Adopted by Duke University, National Institutes of Health, Lee Moffitt and Fox Chase Cancer Centers.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters